Dupixent's COPD data breathe new life into Sanofi stock

22 May 2023
dupixent_large

Positive Phase III results for Sanofi’s (Euronext: SAN) trailblazing biologic Dupixent (dupilumab) could open up a significant opportunity in a new treatment setting.

Long used as a treatment for atopic dermatitis (AD), Sanofi and partner Regeneron Pharmaceuticals (Nasdaq: REGN) have invested heavily in broadening Dupixent’s use in areas where type 2 inflammation is a driving factor.

Other than AD, the product is used to treat asthma, chronic rhinosinusitis, prurigo nodularis and eosinophilic esophagitis, bringing in 2.3 billion euros ($2.5 billion) in the first quarter, an increase of 40%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology